Valvular & structural heart disease

Comparison of Incidence, Prevalence and Death of Aortic Stenosis and Aortic Insufficiency in a Nationwide Korean Study

ESC Heart FailPublished Nationwide Korean study

Authors' conclusion

Over 70% of AVD patients were age ≥ 60 years. The 10 year SR of AS, ASAR and RAS exhibited similar patterns, all of which were lower than the SR for other AVD. AVD portends a worse prognosis in older individuals, males, those with lower income levels and those with comorbidities.

Study context

Population
Patients with newly diagnosed non-rheumatic and rheumatic aortic valve disorders (AVD, ICD-10: I35 and I06), excluding congenital heart disease, National Health Insurance Service in Korea, 2006 through 2017newly diagnosed AVD, female: male = 6:4
Participants
101,895 patients
Comparison
Epidemiology of aortic stenosis (AS), AR, ASAR, RAS, RAR and RASAR
Outcome
Distribution of AVD types

Main finding

As reported in the abstract

  • Among all AVD, AR had the highest distribution

Further findings

OutcomeValues
10 year survival rates (SR)SR of AS, ASAR and RAS were lower than those for AR and RARAS 49.2% · ASAR 50.2% · RAS 51.4% · AR 64.5% · RAR 69.2%

Age of AVD patients

AVD patients age ≥ 60 years
More than 70%

Age-standardized incidence and prevalence · over the decade

Non-rheumatic AVD: incidence remained stable, prevalence increased
Rheumatic AVD: both incidence and prevalence decreased

Adjusted hazard ratio for AVD (risk factors)

Higher in individuals who were older, male, had a lower income level, diabetes mellitus, myocardial infarction, heart failure, atrial fibrillation, stroke, chronic kidney disease or malignant neoplasms

Original publication

Comparison of Incidence, Prevalence and Death of Aortic Stenosis and Aortic Insufficiency in a Nationwide Korean Study. ESC Heart Fail. Published 24 February 2025. doi:10.1002/ehf2.15249

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.